Bär & Karrer advises SK Capital on the acquisition of Swixx BioPharma Group

Bär & Karrer advised US-based private equity investor SK Capital on its acquisition of Swixx BioPharma Group. The transaction concerned SK Capital’s acquisition of Swixx BioPharma Group, a globally active partner in the distribution of biopharmaceutical products with a particular focus on Central and Eastern Europe and Latin America. Bär & Karrer represented SK Capital with a team composed by: Christoph Neeracher and Philippe Seiler, who led the team. The firm also included Therry Lehmann, Thomas Rohde, Romina Lauper, Rahel Brüschweiler, Markus Mezger and Max Winnenburg (all M&A); Susanne Schreiber, Martin Leu and Leotrim Berisha (tax); Markus Wang and Christine Schweikard (IP/IT); Mani Reinert, Li Wei Dutler and Martin Werner (competition); Christian Kunz and Katharina Cardon (data protection); Markus Schott, Julia Stempfel and Jan Grossniklaus (regulatory); Rocco Rigozzi and Patrick Neher (real estate); Laura Widmer and Manuel Schmid (employment); Ralph Malacrida and Colin Giezendanner (financing); and Mariel Hoch (public M&A).

Bär & Karrer advises SK Capital on the acquisition of Swixx BioPharma Group

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads